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Abstract. Background/Aim: Anemia in patients suffering
from end-stage renal failure is currently treated with
Erythropoiesis-Stimulating Agents (ESA). This treatment
needs sufficient iron supplementation to avoid an inadequate
dosage of ESA. Nowadays modern analytical instruments
allow to accurately calculate the content of Hemoglobin
(Hb) in reticulocytes (CHr), that can be used as a guide for
prescribing patients with the appropriate amount of iron.
Patients and Methods: Patients, undergoing hemodialysis,
were retrospectively selected from the database and were
divided in two groups: group A received intravenous (IV)
iron and subcutaneously ESA, and their dosages were
adjusted on the basis of the following parameters: Hb, Mean
corpuscular haemoglobin (MCH), CHr with consequent
MCH/CHr ratio and reticulocyte count determined by the
ADVIA 120 Hematology System of Siemens; group B patients
were administered IV iron and ESA monitoring iron storage,
Hb and ferritin. The aforementioned parameters and the
administered amount of iron and ESA were monitored at
baseline, four and eight months from the begining of the
study. Results: For ESA supplementation, no difference was
observed between the groups at the various observed times.
Despite similar Hb levels, the patients of group A needed
significant lower doses of IV iron (–57.8%) avoiding risks of
organ toxicity and obtaining consequent cost saving of
nearly 1 €/patient/month. Conclusion: The use of CHr and
its related parameters allows the avoidance of overdosage of
IV iron, which can potentially damage organs, and the
reduction of health care direct and indirect costs.
Patients suffering from End-Stage Renal Disease (ESRD)
represent a major health care problem with a significant cost,
should they undergo hemodialysis treatment. Patients lose up
to 5-7 mg of iron during each dialysis treatment and this is a
primary cause of their iron-deficiency anemia (1, 2). There is
also an increased need for iron supplementation to maintain
Hb levels within the optimal range and maximize the
response to ESA (3). As oral iron supplementation is often
ineffective due to both patient non-compliance and
gastrointestinal adverse effects, most dialysis patients receive
IV iron to fill sufficient iron stores (4, 5). However, iron
excess is stored in the liver causing organ toxicity and
inflammation as well as an increased risk of infections (6, 7). 
ESRD patients generally need to be given ESA and IV
iron together to achieve the optimal Hb concentrations (4).
The majority of patients on hemodialysis receive an
IV/subcutaneous ESA dose during each dialysis section (8).
Values of transferrin saturation <20% and serum ferritin
<100 ng/ml require iron supplementation. (9). There are not
specific protocols for IV iron supplementation. Previous
clinical studies have suggested the administration of iron
saccharate at a total dose of 1g/14 days (two administrations
of 500 mg or five of 200 mg) (10) or iron gluconate at a total
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dose of 1g/month (four administrations of 250 mg) (11). This
approach leads to a suboptimal correction of anemia with
consequent strong variations of Hb levels. These Hb
variations are responsible for the continuous adjustments of
iron and ESA dosages. 
Reticulocyte count can represent a simple and cheap
indirect way for the diagnosis of anemia. The count of
erythrocytes by automatic methodologies is important and
some issues of this procedure, such as the imprecision and
inaccuracy due to manual count, have been eliminated. The
quantitative measurement of fluorescence intensity rate
represents a current parameter that completes the diagnostic
value of reticulocyte count. 
Thus, these modern analytical instruments allow to
carefully calculate the CHr: CHr is related to MCH and the
corresponding MCH/CHr ratio is influenced both by the
entity of erythropoiesis stimulation of the marrow and the
iron availability for the Hb synthesis. In this study we have
evaluated the usefulness of CHr (by using MCH/CHr ratio)
as a guide for the prescription of iron in order to reduce the
fluctuations of Hb concentrations in patients undergoing
hemodialysis. Testing ferritin levels is a routinely approach
used to adjust iron supplementation in ESRD patients. 
The aims of this work were: a) to compare the usefulness
and appropriateness of CHr, evaluated by MCH/CHr ratio,
versus ferritin in order to optimally set the iron
supplementation in ESRD patients on dialysis; b) to
consequently assess the cost saving analysis.
Materials and Methods
Population. Fifty Caucasian patients on stable hemodialysis
treatment without high C reactive protein levels were retrospectively
studied based on the data of their records. Eighteen patients were
excluded not having filled the entire database, from which the
laboratory parameters were drawn. Thirty two patients formed the
final population. The selected patients were broken into two groups.
The well matched characteristics of the population were reported in
the Table I. 
Laboratory parameters. Group A received iron and ESA, adjusting
their dosages on the basis of the following parameters: Hb,
MCH/CHr ratio, reticulocyte count (expressed as both absolute
and relative values) by an automated hematology system count
(ADVIA 120 Hematology System of Siemens Healthcare GmbH,
Erlangen, Germany). It is a flow-cytometric analyser using low-
angle and high-angle scatter for the determination of individual
cell volume and Hb concentration (12). CHr is determined by
measuring the volume and Hb concentration of each reticulocyte
and it represents the mean value of Hb mass of each cell (13). This
allows calculation of the following indexes: MCH, CHr with
consequent MCH/CHr ratio and the reticulocyte production index
(IPR). The MCH/CHr ratio guides iron supplementation. A value
<1.0 is indicative of physiologic availability of iron by the
erythrone. A ratio >1.0 reveals iron deficiency and a consequent
need for iron supplementation. Reticulocyte Production Index
(RPI) addresses the administration of ESA; in particular RPI<2.0
indicates a reduced production of reticulocyte by the marrow with
consequent need of ESA treatment; RPI>2.0 indicates a
hyperplastic erythropoiesis and reduction until the withdrawal of
ESA is performed. Vice versa, patients of group B were
administered iron and ESA on the basis of the recommended
guidelines for the treatment of anemia in chronic renal failure of
the Italian Society of Nephrology (14) monitoring iron storage, Hb
and ferritin. The afore mentioned parameters as well as the
administered amount of iron and ESA were monitored at baseline,
at four and eight months of the study. 
Statistics. First of all, data of every studied variable were analyzed
in order to assess the distribution by the Shapiro-Wilk (S-W) test.
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Table I. Characteristics of enrolled patients at baseline.
                                                                                      Group A                                                          Group B                                             p-Value
Number (M/F)                                                               15 (8/7)                                                           17 (8/9)                                               0.803
Age (years)                                                             70.0 (62.0-73.7)                                             73.0 (64.2-77.7)                                        0.199
Duration of dialysis (years)                                      4.0 (3.0-6.5)                                                    3.0 (2.0-6.0)                                           0.392
ESA dose (U/kg/patient/month)                        425.3 (201.5-770.8)*                                    443.2 (217.6-612.9)**                                   0.682
Hb (mg/dL)                                                                   11.2±1.4                                                          11.6±1.0                                              0.388
Ferritin (ng/mL)                                                  286.0 (168.5-337.2)                                       230.0 (159.1-395.8)                                     0.737
*Eight on epoetin zeta, 4 on darbepoetin alfa and 3 on methoxy polyethylene glycol-epoetin beta; **Five on epoetin zeta, 7 on darbepoetin alfa, 4
on methoxy polyethylene glycol-epoetin beta and 1 on epoetin beta.
Table II. Amount of administered ESA (U/kg/patient/month) in both
groups at observed times.
                              T0                              T4                              T8
Group A   425.3 (201.5-770.8)   387.4 (196.5-677.1)  463.8 (248.4-571.3)
Group B   443.2 (217.6-612.9)   442.5 (350.5-529.2)  385.9 (342.1-447.9)
ANOVA 2X2 Design: groups: F=0.99, p=0.323; time: F=0.51, p=0.60;
groups*time: F=0.32, p=0.72.
The normally distributed variables (S-W, p>0.05) were expressed
as mean (M)±standard deviation (SD). Vice versa the abnormally
distributed variables (S-W, p<0.05) were expressed as median
values (InterQuartile Range, IQR). To study frequencies, Chi
squares were used. For the variable Hb, which was normally
distributed, the unpaired t-test was performed to assess the
difference between two groups. When dealing with not normally
distributed variables, the Mann-Whitney test was adopted in order
to evaluate the difference between two groups.
An ANOVA 2×2 analysis was performed to evaluate differences
between the two groups at the investigated times.
A p-value <0.05 was considered significant.
Results
In Table I the characteristics of the studied population at
baseline were reported.
First of all, concerning the ESA supplementation, no
difference was observed between groups and at the observed
times (Table II). Stable values of Hb were present in both
groups at the observed times and no significant difference
was found between the groups A and B (Table III). Despite
these similar Hb levels, the patients of group A needed
significant lower doses of IV trivalent iron (–57.8%). In fact,
the total amount of administered iron in patients of groups A
and B were 11,500 and 19,875 mg, respectively. For ferritin,
although the basal values in both groups were similar, in the
course of treatment its values tended to significantly decrease
in the group A, confirming the minor need for iron
supplementation. Accordingly, MCH/CHr baseline values
were superior to those of group B, with a trend to decrease
during the follow up.
When analyzing the RPI values, no difference was
observed between groups and regards to times, in agreement
with the used doses of ESA.
Furthermore, a pharmacoeconomic evaluation showed a
reduction in the cost of iron therapy of nearly 1 €/patient/
month. 
Discussion
The loss of blood due to hemodialysis procedures but also
laboratory testing is responsible for the anemia that usually
is normocytic, normochromic and slightly regenerative. This
condition needs ESA therapy, which should be associated
with the administration of iron, as its efficacy is strongly
linked to the adequate supplementation of this important
trace metal. Optimal iron dosage is mandatory in order to
avoid inappropriate ectopic storage (particularly liver, spleen,
hearth, endocrine system) with related specific organ injury
(15). In fact, overdose leads to an epidemic overload of iron
in the ESRD population; IV iron bypasses the biological
safeguards for the transport and handling of iron and helps
to intensify chronic kidney disease-associated oxidative
stress and inflammation. As a consequence, indiscriminate
use of IV iron can accelerate cardiovascular disease, promote
microbial infections, aggravate eventual viral hepatitis, and
worsen diabetes and diabetic complications in such patients.
For these reasons IV iron should be judiciously used in this
vulnerable population (6).
Thus, adequate supplementation of both ESA and iron is
central to reaching the Hb target concentrations. With regard
to iron supplementation, IV iron is required as iron absorption
is reduced along the gastro-intestinal tract due to elevation of
hepcidin causing iron deficiency in ESRD patients. Even
slight excess iron as a result of prolonged exposure can lead
to toxicity. This approach could seem to be exaggerated, but
it is mandatory to prevent long-term complications of iron
overload and maintain serum iron and total body iron levels
within a normal range. In this regards, the CHr could
represent a valid diagnostic alternative although conflicting
results exist in the literature. In fact, a previous study reported
that the analysis of CHr is not superior to MCH when
screening for iron deficiency in elderly anemic hospitalized
patients (16). Conversely, other investigations carried out in
animals and humans demonstrated an important predictive
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Table III. Hematologic parameters investigated in both groups at observed times.
Group A                               T0                           T4                           T8                    Group B                  T0                           T4                          T8
Hb (mg/dL)                    11.2±1.4                 11.1±1.4                 10.8±0.9            Hb (mg/dL)           11.6±1.0                 10.7±0.6                11.6±0.6
MCH/CHr                0.95 (0.94-0.96)     0.91 (0.88-0.93)     0.88 (0.87-0.92)       MCH/CHr      0.89 (0.87-0.91)     0.88 (0.87-0.89)    0.88 (0.85-0.91)
RPI                            5.78 (3.87-7.38)     5.00 (4.15-5.83)     6.00 (4.79-6.87)             RPI           6.14 (3.24-7.69)     4.00 (2.55-5.83)    5.87 (4.59-7.70)
Ferritin (ng/mL)               286.0                      116.0                      153.0                  Ferritin                230.0                      213.0                    285.5 
                                   (168.5-337.2)          (48.5-165.0)           (48.5-198.0)            (ng/mL)          (159.1-395.8)         (171.7-345.3)        (241.2-368.5)
                                               
Hb ANOVA 2X2 Design: groups: F=1.56, p=0.214; time: F=2.17, p=0.120; groups*time: F=2.93; p=0.06; MCH/CHr ANOVA 2X2 Design: groups:
F=18.26, p≤0.001; time: F=5.28, p=0.007; groups*time: F=2.25, p=0.11; RPI ANOVA 2X2 Design: groups: F=0.015, p=0.903; time: F=2.19,
p=0.118; groups*time: F=0.132, p=0.876; Ferritin ANOVA 2X2 Design: groups: F=9.66, p=0.0003; time: F=3.739, p=0.028; groups*time: F=2.563,
p=0.083.
role of CHr in the diagnosis of iron deficiency (17). In our
population, patients of group A required minor iron
supplementation based on this recent analytical approach, and
this finding is in agreement with the latter reported study. 
Administering the ideal iron dosage avoids important
fluctuations in ESA dosage, identifies no-responders and
improves health care costs. The cost reduction, due to
tailored iron therapy, could be considered an apparently
inconsistent issue but, taking into account the large number
of patients on haemodialysis in Italy and the prolonged mean
time of treatment (various years), this saving is noteworthy.
Direct medical costs (laboratory tests including also false
positive or true positive results, instrumental measurements
and hospital services) should be further added to the cost of
drug prescriptions. Finally, indirect costs such as those of
morbidity and mortality should be not overlooked (18). 
Medical errors is the third leading cause of death in the
United States, after heart diseases and cancer, according to
recently published findings (19), burdened by skyrocketing
health care costs. Medication errors can occur in deciding
which medicine and dosage regimen to use. Errors in
prescribing include ineffective under-prescribing and
inappropriate over-prescribing (20).
A limitation of this study could be the relatively small
sample size, although a prolonged time of observation should
be considered a strength.
In conclusion, the use of erythrocyte indexes and their
related parameters allows avoidance of over-dosage of IV
iron, which can potentially damage organs, and reduction in
health care direct and indirect costs.
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